Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases.
Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial.
ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -0.18 Decreased by -79.75% | - |
| Apr 25, 24 | -0.14 Decreased by -53.89% | - |
| Feb 1, 24 | -0.08 Increased by +6.13% | - |
| Oct 18, 23 | -0.10 Increased by +38.25% | - |
| Jul 21, 23 | -0.10 Increased by +53.32% | - |
| Apr 24, 23 | -0.09 Increased by +83.64% | - |
| Feb 24, 23 | -0.08 Increased by +85.45% | - |
| Oct 28, 22 | -0.16 Increased by +51.52% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.68 M Decreased by -179.54% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.01 M Decreased by -124.22% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 176.00 K Increased by +N/A% | -1.09 M Decreased by -36.13% | Decreased by -618.75% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.42 M Increased by +32.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -958.00 K Increased by +69.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -896.00 K Increased by +72.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -800.00 K Increased by +85.91% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.11 M Increased by +55.14% | Decreased by N/A% Decreased by N/A% |